Literature DB >> 23180057

[Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society].

A Straube1, C Gaul, S Förderreuther, P Kropp, M Marziniak, S Evers, W H Jost, H Göbel, C Lampl, P S Sándor, A R Gantenbein, H-C Diener.   

Abstract

Chronic migraine (CM) was first defined in the second edition of the International Headache Society (IHS) classification in 2004. The definition currently used (IHS 2006) requires the patient to have headache on more than 15 days/month for longer than 3 months and a migraine headache on at least 8 of these monthly headache days and that there is no medication overuse. In daily practice the majority of the patients with CM also report medication overuse but it is difficult to determine whether the use is the cause or the consequence of CM. Most the patients also have other comorbidities, such as depression, anxiety and chronic pain at other locations. Therapy has to take this complexity into consideration and is generally multimodal with behavioral therapy, aerobic training and pharmacotherapy. The use of analgesics should be limited to fewer than 15 days per month and use of triptans to fewer than 10 days per month. Drug treatment should be started with topiramate, the drug with the best scientific evidence. If there is no benefit, onabotulinum toxin A (155-195 Units) should be used. There is also some limited evidence that valproic acid and amitriptyline might be beneficial. Neuromodulation by stimulation of the greater occipital nerve or vagal nerve is being tested in studies and is so far an experimental procedure only.

Entities:  

Mesh:

Year:  2012        PMID: 23180057     DOI: 10.1007/s00115-012-3680-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  67 in total

1.  Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial.

Authors:  C-P Yang; M-H Chang; P-E Liu; T-C Li; C-L Hsieh; K-L Hwang; H-H Chang
Journal:  Cephalalgia       Date:  2011-10-21       Impact factor: 6.292

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

5.  Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey.

Authors:  Gretchen E Tietjen; Jan L Brandes; B Lee Peterlin; Arnolda Eloff; Rima M Dafer; Michael R Stein; Ellen Drexler; Vincent T Martin; Susan Hutchinson; Sheena K Aurora; Ana Recober; Nabeel A Herial; Christine Utley; Leah White; Sadik A Khuder
Journal:  Headache       Date:  2009-10-21       Impact factor: 5.887

6.  Family history for chronic headache and drug overuse as a risk factor for headache chronification.

Authors:  Sabina Cevoli; Elisa Sancisi; Daniela Grimaldi; Giulia Pierangeli; Stefano Zanigni; Marianna Nicodemo; Pietro Cortelli; Pasquale Montagna
Journal:  Headache       Date:  2009-03       Impact factor: 5.887

Review 7.  Obesity, migraine, and chronic migraine: possible mechanisms of interaction.

Authors:  Marcelo E Bigal; Richard B Lipton; Philip R Holland; Peter J Goadsby
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.

Authors:  M E Bigal; A M Rapoport; F D Sheftell; S J Tepper; R B Lipton
Journal:  Cephalalgia       Date:  2004-06       Impact factor: 6.292

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

10.  Prevalence and associated factors for episodic and chronic daily headache in the Colombian population.

Authors:  M Rueda-Sánchez; L A Díaz-Martínez
Journal:  Cephalalgia       Date:  2008-03       Impact factor: 6.292

View more
  8 in total

Review 1.  [Peppermint oil in the acute treatment of tension-type headache].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn; A Göbel; C Göbel
Journal:  Schmerz       Date:  2016-06       Impact factor: 1.107

Review 2.  [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society].

Authors:  R Ruscheweyh; S Förderreuther; C Gaul; A Gendolla; D Holle-Lee; T Jürgens; L Neeb; A Straube
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

3.  [Relaxation techniques and behavioural therapy for the treatment of migraine : Guidelines from the German Migraine and Headache Society].

Authors:  P Kropp; B Meyer; T Dresler; G Fritsche; C Gaul; U Niederberger; S Förderreuther; V Malzacher; T P Jürgens; M Marziniak; A Straube
Journal:  Schmerz       Date:  2017-10       Impact factor: 1.107

4.  [Botulinum toxin type A in headache treatment : Established and experimental indications].

Authors:  C Gaul; D Holle-Lee; A Straube
Journal:  Nervenarzt       Date:  2016-08       Impact factor: 1.214

5.  [Classification and therapy of medication-overuse headache: impact of the third edition of the International Classification of Headache Disorders].

Authors:  H Göbel; K Heinze-Kuhn; I Petersen; C Göbel; A Göbel; A Heinze
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 6.  Hints on Diagnosing and Treating Headache.

Authors:  Arne May
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

Review 7.  Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Authors:  Claus M Escher; Lejla Paracka; Dirk Dressler; Katja Kollewe
Journal:  Ther Adv Neurol Disord       Date:  2016-11-16       Impact factor: 6.570

8.  Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial.

Authors:  Abolghasem Rahimdel; Ali Mellat; Ahmad Zeinali; Elahe Jafari; Parisa Ayatollahi
Journal:  Iran J Med Sci       Date:  2014-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.